Deepa Rangachari1, Paul A VanderLaan2, Xiuning Le1, Erik Folch3, Michael S Kent4, Sidharta P Gangadharan4, Adnan Majid3, Richard L Haspel2, Loren J Joseph2, Mark S Huberman1, Daniel B Costa1. 1. Department of Medicine, 330 Brookline Avenue, Boston, MA 02215, USA. 2. Department of Pathology, 330 Brookline Avenue, Boston, MA 02215, USA. 3. Department of Medicine, 330 Brookline Avenue, Boston, MA 02215, USA ; Department of Surgery, 330 Brookline Avenue, Boston, MA 02215, USA; all at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 4. Department of Surgery, 330 Brookline Avenue, Boston, MA 02215, USA; all at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Abstract
INTRODUCTION: Tumor genotyping using single gene assays (SGAs) is standard practice in advanced non-small-cell lung cancer (NSCLC). We evaluated how the introduction of next generation sequencing (NGS) into day-to-day clinical practice altered therapeutic decision-making. METHODS: Clinicopathologic data, tumor genotype, and clinical decisions were retrospectively compiled over 6 months following introduction of NGS assay use at our institution in 82 patient-tumor samples (7 by primary NGS, 22 by sequential SGAs followed by NGS, and 53 by SGAs). RESULTS: SGAs identified abnormalities in 34 samples, and all patients with advanced EGFR-mutated or ALK-rearranged tumors received approved tyrosine kinase inhibitors (TKIs) or were consented for clinical trials. NGS was more commonly requested for EGFR, ALK, and KRAS-negative tumors (p<0.0001). NGS was successful in 24/29 (82.7%) tumors. Of 17 adenocarcinomas (ACs), 11 (7 from patients with ≤15 pack-years of smoking) had abnormalities in a known driver oncogene. This led to a change in decision-making in 8 patients, trial consideration in 6, and off-label TKI use in 2. Of 7 squamous cell (SC) carcinomas, 1 had a driver aberration (FGFR1); 6 had other genomic events (all with TP53 mutations). In no cases were clinical decisions altered (p=0.0538 when compared to ACs). CONCLUSIONS: Targeted NGS can identify a significant number of therapeutically-relevant driver events in lung ACs; particularly in never or light smokers. For SC lung cancers, NGS is less likely to alter current practice. Further research into the cost effectiveness and optimal use of NGS and improved provider training in genomic oncology are warranted.
INTRODUCTION:Tumor genotyping using single gene assays (SGAs) is standard practice in advanced non-small-cell lung cancer (NSCLC). We evaluated how the introduction of next generation sequencing (NGS) into day-to-day clinical practice altered therapeutic decision-making. METHODS: Clinicopathologic data, tumor genotype, and clinical decisions were retrospectively compiled over 6 months following introduction of NGS assay use at our institution in 82 patient-tumor samples (7 by primary NGS, 22 by sequential SGAs followed by NGS, and 53 by SGAs). RESULTS: SGAs identified abnormalities in 34 samples, and all patients with advanced EGFR-mutated or ALK-rearranged tumors received approved tyrosine kinase inhibitors (TKIs) or were consented for clinical trials. NGS was more commonly requested for EGFR, ALK, and KRAS-negative tumors (p<0.0001). NGS was successful in 24/29 (82.7%) tumors. Of 17 adenocarcinomas (ACs), 11 (7 from patients with ≤15 pack-years of smoking) had abnormalities in a known driver oncogene. This led to a change in decision-making in 8 patients, trial consideration in 6, and off-label TKI use in 2. Of 7 squamous cell (SC) carcinomas, 1 had a driver aberration (FGFR1); 6 had other genomic events (all with TP53 mutations). In no cases were clinical decisions altered (p=0.0538 when compared to ACs). CONCLUSIONS: Targeted NGS can identify a significant number of therapeutically-relevant driver events in lung ACs; particularly in never or light smokers. For SC lung cancers, NGS is less likely to alter current practice. Further research into the cost effectiveness and optimal use of NGS and improved provider training in genomic oncology are warranted.
Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316
Authors: Richard L Haspel; Randall J Olsen; Anna Berry; Charles E Hill; John D Pfeifer; Iris Schrijver; Karen L Kaul Journal: Arch Pathol Lab Med Date: 2014-04 Impact factor: 5.534
Authors: David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Stefan C Grant; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Feng-Ming Spring Kong; Mark G Kris; Lee M Krug; Rudy P Lackner; Inga T Lennes; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Douglas E Wood; Stephen C Yang; Kristina Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2013-06-01 Impact factor: 11.908
Authors: Stacy W Gray; Katherine Hicks-Courant; Christopher S Lathan; Levi Garraway; Elyse R Park; Jane C Weeks Journal: J Oncol Pract Date: 2012-08-07 Impact factor: 3.840
Authors: Paul A Vanderlaan; Norihiro Yamaguchi; Erik Folch; David H Boucher; Michael S Kent; Sidharta P Gangadharan; Adnan Majid; Michael A Goldstein; Mark S Huberman; Olivier N Kocher; Daniel B Costa Journal: Lung Cancer Date: 2014-01-28 Impact factor: 5.705
Authors: Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: Norihiro Yamaguchi; Paul A Vanderlaan; Erik Folch; David H Boucher; Hannah M Canepa; Michael S Kent; Sidharta P Gangadharan; Adnan Majid; Olivier N Kocher; Michael A Goldstein; Mark S Huberman; Daniel B Costa Journal: Lung Cancer Date: 2013-08-07 Impact factor: 5.705
Authors: Deepa Rangachari; Paul A VanderLaan; Meghan Shea; Xiuning Le; Mark S Huberman; Susumu S Kobayashi; Daniel B Costa Journal: J Thorac Oncol Date: 2017-01-16 Impact factor: 15.609
Authors: Daniel B Costa; Susan E Jorge; Jason P Moran; Jason A Freed; Jessica A Zerillo; Mark S Huberman; Susumu S Kobayashi Journal: J Thorac Oncol Date: 2016-03-08 Impact factor: 15.609
Authors: Antonio R Lucena-Araujo; Jason P Moran; Paul A VanderLaan; Dora Dias-Santagata; Erik Folch; Adnan Majid; Michael S Kent; Sidharta P Gangadharan; Deepa Rangachari; Mark S Huberman; Susumu S Kobayashi; Daniel B Costa Journal: Lung Cancer Date: 2016-06-14 Impact factor: 5.705
Authors: Paul A VanderLaan; Deepa Rangachari; Adnan Majid; Mihir S Parikh; Sidharta P Gangadharan; Michael S Kent; Danielle C McDonald; Mark S Huberman; Susumu S Kobayashi; Daniel B Costa Journal: Lung Cancer Date: 2018-01-04 Impact factor: 5.705
Authors: Robert D Schouten; Daan C L Vessies; Linda J W Bosch; Nicole P Barlo; Anne S R van Lindert; Saskia A G M Cillessen; Daan van den Broek; Michel M van den Heuvel; Kim Monkhorst Journal: JCO Precis Oncol Date: 2021-07-09
Authors: Vanda F Torous; Deepa Rangachari; Benjamin P Gallant; Meghan Shea; Daniel B Costa; Paul A VanderLaan Journal: J Am Soc Cytopathol Date: 2018-02-16